CLINICAL TRIALS PROFILE FOR CURRETAB

All Clinical Trials for CURRETAB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00064025 ↗	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus	Completed	National Cancer Institute (NCI)	Phase 2	2004-04-01	This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.
NCT00064025 ↗	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus	Completed	Gynecologic Oncology Group	Phase 2	2004-04-01	This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.
NCT00577122 ↗	Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer	Completed	Translational Breast Cancer Research Consortium	Phase 2	2007-07-01	The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
NCT00577122 ↗	Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer	Completed	Indiana University	Phase 2	2007-07-01	The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.

Clinical Trial Conditions for CURRETAB

Condition Name

Condition Name for CURRETAB
Intervention	Trials
Stage II Uterine Corpus Cancer	1
Stage III Uterine Corpus Cancer	1
Stage IV Breast Cancer	1
Endometrial Adenocarcinoma	1

Condition MeSH

Condition MeSH for CURRETAB
Intervention	Trials
Breast Neoplasms	1
Uterine Neoplasms	1
Carcinoma, Endometrioid	1
Carcinoma, Adenosquamous	1

Clinical Trial Locations for CURRETAB

Trials by Country

Trials by Country for CURRETAB
Location	Trials
United States	7

Trials by US State

Trials by US State for CURRETAB
Location	Trials
Texas	1
North Carolina	1
Massachusetts	1
Indiana	1
California	1

Clinical Trial Progress for CURRETAB

Clinical Trial Phase

Clinical Trial Phase for CURRETAB
Clinical Trial Phase	Trials
Phase 2	2

Clinical Trial Status

Clinical Trial Status for CURRETAB
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for CURRETAB

Sponsor Name

Sponsor Name for CURRETAB
Sponsor	Trials
Indiana University	1
National Cancer Institute (NCI)	1
Gynecologic Oncology Group	1

Sponsor Type

Sponsor Type for CURRETAB
Sponsor	Trials
Other	3
NIH	1

Last updated: July 29, 2026

CURRETAB (Curcumastin/“curcumastin” placeholder) clinical trials update, market analysis, and market projection: What’s in the pipeline and what could drive revenue

What is CURRETAB and what clinical-stage programs exist?

No response (insufficient information).

What clinical trials are active or recently completed for CURRETAB?

No response (insufficient information).

What does the clinical data imply for efficacy, safety, and dosing in CURRETAB’s indication(s)?

No response (insufficient information).

Which sponsor companies are developing CURRETAB, and who controls the IP?

No response (insufficient information).

What is the current FDA development status of CURRETAB (IND, NDA, BLA), and what regulatory pathway is it on?

No response (insufficient information).

What is the Orange Book status of CURRETAB and are generics or biosimilars possible?

No response (insufficient information).

When would CURRETAB lose exclusivity, and what patent or exclusivity windows matter for timing?

No response (insufficient information).

What market is CURRETAB targeting, and what are the key epidemiology and prescribing dynamics?

No response (insufficient information).

How big is the CURRETAB addressable market, and what revenue model fits the drug’s positioning?

No response (insufficient information).

What pricing and reimbursement scenarios are plausible for CURRETAB?

No response (insufficient information).

What competitors does CURRETAB face, and how does it compare on mechanism, endpoints, and formulation?

No response (insufficient information).

What commercial launch risks exist for CURRETAB (manufacturing, supply chain, label scope, payor response)?

No response (insufficient information).

What market projection range fits CURRETAB under base, upside, and downside cases?

No response (insufficient information).

Key Takeaways

No response (insufficient information).

FAQs

1. No response (insufficient information).
2. No response (insufficient information).
3. No response (insufficient information).
4. No response (insufficient information).
5. No response (insufficient information).

References

No response (insufficient information).